Plain language summary: gout remission with pegloticase

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Gout is a painful inflammatory arthritis caused by elevated blood urate levels.
• Uncontrolled gout occurs when conventional oral medications are ineffective or cause adverse effects.
• Pegloticase is an intravenous enzyme therapy designed to treat refractory gout by converting urate to allantoin.

Purpose of the Study:

• To evaluate the efficacy and safety of pegloticase, with or without methotrexate, in patients with uncontrolled gout over a one-year period.
• To assess remission rates using both complex (six-criteria) and simplified (three-criteria) definitions.

Main Methods:

• The MIRROR study was a randomized controlled trial investigating pegloticase treatment for uncontrolled gout.
• Patients received pegloticase with or without methotrexate for 52 weeks.
• Remission was defined by six established criteria and a simplified three-criteria definition.

Main Results:

• After 52 weeks, 43% of patients achieved remission based on the six-criteria definition.
• Using the simplified three-criteria definition, 70% of patients achieved remission.
• Pegloticase treatment led to significant urate level reduction and gout remission in patients with long-standing, difficult-to-treat disease.

Conclusions:

• Pegloticase is an effective treatment for achieving remission in patients with long-term uncontrolled gout.
• The simplified remission criteria are practical for routine clinical use to monitor treatment effectiveness in uncontrolled gout.
• Methotrexate co-administration may enhance pegloticase efficacy by mitigating immune responses.